06.02.21 KZR-616, A Selective Immunoproteasome Inhibitor for the Treatment of Systemic Lupus Erythematosus: Results From the Completed Dose Escalation Phase 1b Portion of the MISSION Study. European Congress of Rheumatology 2021 (EULAR 2021).
